GRANOCYTE-34

Dose: 19.2 Mllion Units/ Sq.meter
Single Dose: 19 (19.2)
Frequency: 24 hourly
Route: SC,IV Inf
Instructions: Started the day after transplantation /chemotherapy completion.

Dose: 19.2 million unit/sq metre
Single Dose: 35 (35)
Frequency: 24 hourly
Route: IV Infusion
Instructions: Not use more than 28 days .Dose recommended for paeds over 2 Yrs

. It is of Semi Synthetic origin. It belongs to Granulocyte colony stimulating factor agonist pharmacological group on the basis of mechanism of action and also classified in Hematological Agents pharmacological group.

Lenograstim is contraindicated in conditions like Kostmans syndrome.

The severe or irreversible adverse effects of Lenograstim, which give rise to further complications include Anemia, Anemia, Thrombocytopenia, Disturbed hepatic function, Disturbed hepatic function, Anemia, Anemia.The symptomatic adverse reactions produced by Lenograstim are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Diarrhea, Hypotension, Bone pain, Vasculitis, Uricemia, Proteinuria, Musculoskeletal pain, Epistaxis.

Lenograstim is primarily indicated in conditions like Bone marrow transplantation, Cytotoxic-induced neutropenia, Mobilisation of peripheral blood progenitor cells, Neutropenia, Reduction in the duration of neutropenia following bone marrow transplantation.

No data regarding the interactions of Lenograstim was found.

If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Inj, Inf Store in refrigerator.

Caution should be taken if tumours with myeloid characteristics (risk of the tumour growth), pre-malignant myeloid conditions is present. Reduced myeloid precursors, monitor leucocyte count (discontinue treatment if leucocylossis); monitor platelet count and hemoglobin; regular morphological and cytogenetic bone marrow examinations recommended in severe congenital neutropenia (possible risk of myelodysplastic syndromes or leukemia) monitor spleen size, osteoporotic bone disease ( monitor bone marrow densityif given for more than 6 months).